News

APP Pharmaceuticals develops, manufactures and markets injectable pharmaceutical products with a primary focus on the oncology, anti-infective, anesthetic/analgesic and critical care markets. Gemcitabine HCI for Injection is indicated

RG3039, an orally bioavailable compound, is an inhibitor of an RNA processing enzyme which targets SMN2. The trial is designed to investigate the safety and pharmacokinetic of escalating

The results of the trial suggested that olaparib 400mg twice daily extended progression free survival (PFS) by RECIST compared to placebo Median PFS: 8.4 vs 4.8 months respectively.

Synergy Outsourcing, part of UK based scientific recruiter SRG, is a functional service provider of on and off site outsourced services across the chemistry, quality and biochemistry industries.

MetMAb, a monovalent (one-armed), monoclonal antibody is designed to block Met signaling in cancer cells by binding specifically to the cell surface Met receptor, blocking HGF-mediated activation. MetMAb

TissueGene expects to recruit around 100 patients in the trial across US. In the Phase II trial, the patients will be given intra-articular injection of either TG-C or

Imprime PGG is a novel immunomodulatory drug in development as a cancer therapy. The company expects to recruit around 795 patients in over 50 locations worldwide, including the

Dexamethasone elixir, a corticosteroid, is indicated for the treatment for variety of conditions including endocrine disorders, rheumatic disorders, and collagen diseases. Dexamethasone elixir works by decreasing or preventing

The acquisition will allow Takeda to add roflumilast franchise (Daxas; trade name in Europe), indicated as the treatment for chronic obstructive pulmonary disease (COPD), into its product portfolio